AstraZeneca Announces Positive Phase III Results for Ultomiris in Generalized Myasthenia Gravis
AstraZeneca has reported positive Phase III trial results for Ultomiris (ravulizumab) in adults with generalized myasthenia gravis. The CHAMPION-NMOSD study met its primary endpoint, showing significant improvements in disease severity and daily functioning. AstraZeneca intends to submit these findings to regulatory authorities for potential label ...
- Published date: 31-07-2026 10:02 AM
AstraZeneca has announced positive results from its Phase III CHAMPION-NMOSD trial evaluating Ultomiris (ravulizumab) for the treatment of adults with generalized myasthenia gravis (gMG). The study met its primary endpoint, demonstrating a statistically significant reduction in disease severity compared to placebo.
The trial results showed that patients receiving Ultomiris experienced improvements in muscle strength and daily functioning, with a safety profile consistent with previous studies. These findings support the potential of Ultomiris as a new treatment option for adults living with gMG.
AstraZeneca plans to submit these data to regulatory authorities in Europe and globally, aiming to expand the approved indications for Ultomiris. More information about the trial can be found on AstraZeneca's official website.
AstraZeneca has reported positive Phase III trial results for Ultomiris (ravulizumab) in adults with generalized myasthenia gravis. The CHAMPION-NMOSD study met its primary endpoint, showing significant improvements in disease severity and daily functioning. AstraZeneca intends to submit these findings to regulatory authorities for potential label expansion.